New combo therapy shows promise against advanced kidney cancer
NCT ID NCT02853331
Summary
This study tested whether a new two-drug combination works better than the standard single-drug treatment for advanced kidney cancer that has spread. It involved 861 people who had not yet received treatment for their advanced cancer. Researchers compared the combination of pembrolizumab (an immunotherapy) and axitinib (a targeted therapy) against sunitinib, the standard treatment, to see which helped patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.